Real-world costs of autosomal dominant polycystic kidney disease in the Nordics
Abstract Background There is limited real-world data on the economic burden of patients with autosomal dominant polycystic kidney disease (ADPKD). The objective of this study was to estimate the annual direct and indirect costs of patients with ADPKD by severity of the disease: chronic kidney diseas...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-08-01
|
| Series: | BMC Health Services Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12913-017-2513-8 |
| _version_ | 1828530042205896704 |
|---|---|
| author | Daniel Eriksson Linda Karlsson Oskar Eklund Hans Dieperink Eero Honkanen Jan Melin Kristian Selvig Johan Lundberg |
| author_facet | Daniel Eriksson Linda Karlsson Oskar Eklund Hans Dieperink Eero Honkanen Jan Melin Kristian Selvig Johan Lundberg |
| author_sort | Daniel Eriksson |
| collection | DOAJ |
| description | Abstract Background There is limited real-world data on the economic burden of patients with autosomal dominant polycystic kidney disease (ADPKD). The objective of this study was to estimate the annual direct and indirect costs of patients with ADPKD by severity of the disease: chronic kidney disease (CKD) stages 1–3; CKD stages 4–5; transplant recipients; and maintenance dialysis patients. Methods A retrospective study of ADPKD patients was undertaken April–December 2014 in Denmark, Finland, Norway and Sweden. Data on medical resource utilisation were extracted from medical charts and patients were asked to complete a self-administered questionnaire. Results A total of 266 patients were contacted, 243 (91%) of whom provided consent to participate in the study. Results showed that the economic burden of ADPKD was substantial at all levels of the disease. Lost wages due to reduced productivity were large in absolute terms across all disease strata. Mean total annual costs were highest in dialysis patients, driven by maintenance dialysis care, while the use of immunosuppressants was the main cost component for transplant care. Costs were twice as high in patients with CKD stages 4–5 compared to CKD stages 1–3. Conclusions Costs associated with ADPKD are significant and the progression of the disease is associated with an increased frequency and intensity of medical resource utilisation. Interventions that can slow the progression of the disease have the potential to lead to substantial reductions in costs for the treatment of ADPKD. |
| first_indexed | 2024-12-11T22:17:29Z |
| format | Article |
| id | doaj.art-cd5f37c37b7b44d4b166b9f25ffc70e3 |
| institution | Directory Open Access Journal |
| issn | 1472-6963 |
| language | English |
| last_indexed | 2024-12-11T22:17:29Z |
| publishDate | 2017-08-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Health Services Research |
| spelling | doaj.art-cd5f37c37b7b44d4b166b9f25ffc70e32022-12-22T00:48:33ZengBMCBMC Health Services Research1472-69632017-08-011711910.1186/s12913-017-2513-8Real-world costs of autosomal dominant polycystic kidney disease in the NordicsDaniel Eriksson0Linda Karlsson1Oskar Eklund2Hans Dieperink3Eero Honkanen4Jan Melin5Kristian Selvig6Johan Lundberg7Quantify ResearchQuantify ResearchQuantify ResearchOdense University Hospital, Department of NephrologyHelsinki University Central Hospital, Department of Medicine, Division of NephrologyUppsala University Hospital, Department of NephrologyVestre Viken Hospital Trust, Department of NephrologyOtsuka Pharma ScandinaviaAbstract Background There is limited real-world data on the economic burden of patients with autosomal dominant polycystic kidney disease (ADPKD). The objective of this study was to estimate the annual direct and indirect costs of patients with ADPKD by severity of the disease: chronic kidney disease (CKD) stages 1–3; CKD stages 4–5; transplant recipients; and maintenance dialysis patients. Methods A retrospective study of ADPKD patients was undertaken April–December 2014 in Denmark, Finland, Norway and Sweden. Data on medical resource utilisation were extracted from medical charts and patients were asked to complete a self-administered questionnaire. Results A total of 266 patients were contacted, 243 (91%) of whom provided consent to participate in the study. Results showed that the economic burden of ADPKD was substantial at all levels of the disease. Lost wages due to reduced productivity were large in absolute terms across all disease strata. Mean total annual costs were highest in dialysis patients, driven by maintenance dialysis care, while the use of immunosuppressants was the main cost component for transplant care. Costs were twice as high in patients with CKD stages 4–5 compared to CKD stages 1–3. Conclusions Costs associated with ADPKD are significant and the progression of the disease is associated with an increased frequency and intensity of medical resource utilisation. Interventions that can slow the progression of the disease have the potential to lead to substantial reductions in costs for the treatment of ADPKD.http://link.springer.com/article/10.1186/s12913-017-2513-8Polycystic kidney diseasesADPKDHealth Care CostsHealth ExpendituresCost of Illness |
| spellingShingle | Daniel Eriksson Linda Karlsson Oskar Eklund Hans Dieperink Eero Honkanen Jan Melin Kristian Selvig Johan Lundberg Real-world costs of autosomal dominant polycystic kidney disease in the Nordics BMC Health Services Research Polycystic kidney diseases ADPKD Health Care Costs Health Expenditures Cost of Illness |
| title | Real-world costs of autosomal dominant polycystic kidney disease in the Nordics |
| title_full | Real-world costs of autosomal dominant polycystic kidney disease in the Nordics |
| title_fullStr | Real-world costs of autosomal dominant polycystic kidney disease in the Nordics |
| title_full_unstemmed | Real-world costs of autosomal dominant polycystic kidney disease in the Nordics |
| title_short | Real-world costs of autosomal dominant polycystic kidney disease in the Nordics |
| title_sort | real world costs of autosomal dominant polycystic kidney disease in the nordics |
| topic | Polycystic kidney diseases ADPKD Health Care Costs Health Expenditures Cost of Illness |
| url | http://link.springer.com/article/10.1186/s12913-017-2513-8 |
| work_keys_str_mv | AT danieleriksson realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics AT lindakarlsson realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics AT oskareklund realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics AT hansdieperink realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics AT eerohonkanen realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics AT janmelin realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics AT kristianselvig realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics AT johanlundberg realworldcostsofautosomaldominantpolycystickidneydiseaseinthenordics |